生物制药公司Altimmune, Inc.（股票代码：ALT）今日盘前股价大幅下挫，跌幅高达61.48%，引起市场广泛关注。这一剧烈波动与该公司最新公布的临床试验结果密切相关。
Altimmune周四发布了其用于治疗肥胖症的实验性药物pemvidutide的中期试验结果。该试验主要研究这种药物对脂肪肝的潜在治疗效果。结果显示，在212名患者参与的试验中，高达59.1%的参与者的代谢功能障碍相关性脂肪性肝炎（MASH）或非酒精性脂肪性肝炎（NASH）症状有所缓解，且肝脏瘢痕没有恶化。此外，试验中患者的体重平均减轻了6.2%。
然而，尽管达到了主要试验目标，但投资者对结果似乎并不满意。Citizensbank分析师乔纳森·沃勒本指出，虽然总体数据看起来不错，但在改善肝脏瘢痕或纤维化方面缺乏统计学意义，这一点让投资者难以接受。这可能是导致股价大跌的主要原因。目前，pemvidutide作为一种肥胖症治疗药物正在单独进行研究，市场将密切关注其后续发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.